LC-MS, Biomarker Discovery Research
Depletion & Enrichment
DNA & RNA Research
Our products are sold worldwide into growing research markets including publicly sponsored research, academia, and commercial biopharmaceuticals. The proteomics market is driven by technological advancements in Liquid Chromatography coupled to Mass Spectrometry instrumentation. This has allowed for rapid methods development to support peptide and protein sequence annotation, along with label and label-free quantitation of peptide, proteins and their post-translational modifications. Public repositories of genomic, transcription and now proteomic data can now be mined to profile disease and personalize medical treatment options. Our products help to make such data possible, more efficient and more cost-effective.
Furthermore , most efforts in proteomics seek to identify and sequence annotate the proteome by LC-MS analyses of peptides derived through proteolytic processing. While such efforts have been very productive, a critical assumption is that function is linearly proportional to protein abundance. However, this is often not the case as conformational variability affects functional activity in a non-linear fashion. In different tissues, or under stress or disease conditions, protein sequences that are normally associated with one function, may perform alternative functions - that is what we call the multi-functional proteome. This multi-functional proteome can now be monitored, cataloged and annotated, first by resolving functionally active proteins, and from there, sequence and structurally annotating the subset proteome that presents that function. As a consequence, functionally measured biomarkers may provide a higher dynamic range or more discreet characterization than abundance based biomarkers. Functional Proteomics therefore supports top-down discovery strategies that start with functional annotation of the structurally intact protein, and ends with sequence and structural annotation. Such strategies demand separations that retain function and structural integrity – a feature of all of our products.
Business Plan Potential
The company is poised for rapid growth as cost effective and efficient sample prep methods will be essential for expanding markets. We foresee:
1. Continued growth in the consumable research area following the installation of LC-MS instrument and computational infrastructure.
2. Cultural and technological disruptions forthcoming in heathcare. Particularly, we foresee personalized health monitoring with adoption of protein marker base-lining for high risk individuals for diabetes, cancer, cardiovascular, and neurodegenerative disorders. Such monitoring will require collection of biological fluids such as blood, urine or saliva and simple ways to either measure with over-the-counter kits, or preserve and mail to specialized laboratories. All such methods will require specialized sample prep and enrichment technologies.
3. The integration of therapeutics, diagnostics and biomarkers into personalized medicine will demand engagement with many ‘omic’ technologies. We envision through biopharm partnerships, growing a knowledgebase in functional and chemical proteomics. From such a knowledgebase, biomarker assets surrounding chemical interactomes, disordered sequence and multifunctional proteomes will be derived.
Our DNA isolation product – ProCipitate™ was used throughout the Human Genome Sequencing Project.
We have a worldwide customer base, including key reagent supply for Battelle National Laboratories, Cleveland Clinic, Morton General Hospital (Seattle), Mount Sinai School of Medicine (New York), USDA (Ames, IA), US Center for Disease Control, US Federal Drug Administration, and US Army Medical Research Institute. The variety of research areas include cancer, Alzheimer’s, malaria, diabetes, neurological and Food Environmental Safety.
We pioneered Functional Proteomics separations and On-Bead Digestion of complex proteomes.
- We were the first to use bead-based separations to distinguish a related tissue using a functional biomarker from a complex proteome solely based on enzymatic reactions and substrate selection.
- We were the first to use on-bead digestion of an albumin depleted serum proteome with demonstrated improvements of workflow and protein annotations, compared to alternative depletion and in-solution methods.
- From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients.
We collaborate with Rutgers Proteomics Center on methods to improve LC-MS workflows so as to provide cost-effective data output.
We collaborate with ArrayBridge (St. Louis, MO) on new gel-based functional proteomic strategies, and methods to sequence annotate the multi-functional proteome.
We collaborate with Process Stream (Princeton, NJ) on bioinformatics and computational methods.
Biotech Support Group has mentored many students and interns who subsequently achieved advanced degrees and placement in a variety of professions. We are constantly seeking motivated people, regardless of experience with interest and aptitude in proteomics research, marketing, sales, and bioinformatics. If you think that you contribute to our company’s success, please contact us at our main office by telephone or email.